Home  /  Resource Library  /  Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B-cell lymphoma

Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B-cell lymphoma

Results of a study investigating durvalumab combined with ibrutinib for treatment of relapsed follicular or DLBCL.